alzheimer's disease
Conditions
Interventions
Treatment group:20% Aromatic Chinese herbal essential oil ointment
Control:0.1% Aromatic Chinese herbal essential oil ointment
Sponsors
Hospital of Kunming Social Welfare Institution
Eligibility
Sex/Gender
All
Age
60 Years to 100 Years
Inclusion criteria
Inclusion criteria: 4. Selection of the research population Diagnostic criteria Referring to the clinical criteria of the Mental and Behavioral Disorders Classification F00 of the International Classification of Diseases, 10th Edition (ICD-10), Alzheimer's disease dementia, as follows: (a) The presence of dementia as described above; (b) It has an insidious onset and a slow progression. Usually, it is difficult to specify the exact time of the disease, but others will suddenly notice the presence of symptoms. During the disease's progression, there will be a distinct plateau period. (c) There is no clinical evidence or special examination results to suggest that the mental disorder is caused by other systemic diseases or brain diseases that can lead to dementia. (d) There is a lack of sudden, stroke-like attacks, and no signs of focal neurological damage in the early stage of the disease. Including F00.0 Early-onset Alzheimer's disease dementia and senile dementia; F00.1 Late-onset Alzheimer's disease dementia, senile dementia; F00.2 Atypical or mixed Alzheimer's disease dementia; F00.9 Unspecified Alzheimer's disease dementia. (2) Inclusion criteria 1) Meet the above diagnostic criteria for symptoms; 2) The severity of dementia is mild to moderate, and the score of the Brief Neuropsychological Test (MMSE) is between 10 and 26 points (the baseline diagnosis of dementia uses the MMSE education adjustment value: university =26 points, middle school =24 points, primary school =23 points, illiterate =22 points). 3) Have a stable caregiver; 4) Informed consent: The guardian shall sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1) Clinical diseases that meet the diagnostic criteria for vascular dementia include acute vascular dementia, dementia caused by multiple cerebral infarctions, subcortical vascular dementia, mixed cortical and subcortical vascular dementia, and other unspecified vascular dementias. ; 2) Other types of dementia, such as frontotemporal dementia, Lewy body dementia, and dementia secondary to infections, poisoning, metabolism, tumors, traumatic brain injuries, etc. 3) Have a history of epilepsy or Parkinson's disease; 4) Other poorly controlled systemic diseases, such as severe arrhythmia or patients who have experienced myocardial infarction within 3 months before participating in the trial, or severe heart failure, or severe hypotension or hypertension; 5) Patients with allergic constitutions, such as those suffering from asthma, allergic rhinitis, or those allergic to the drugs studied in this study; 6) The researcher believes that there are other circumstances that make participation in this clinical trial unsuitable.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Alzheimer's Disease Rating Scale Cognitive Scale; | — |
Secondary
| Measure | Time frame |
|---|---|
| Pathological Behavior Rating Scale for Alzheimer's Disease;Dementia of Traditional Chinese Medicine Syndrome Scale;biomarkers associated with neurodegenerative pathology, namely the levels of Amyloid-Beta 1-42, Amyloid-Beta 1-40, phosphorylated Tau protein at threonine 181, phosphorylated Tau protein at threonine 217, Glial Fibrillary Acidic Protein, and Neurofilament Light Chain protein;Inflammation-related markers Interleukin-6, Tumor Necrosis Factor-alpha, and C-Reactive Protein;Changes in the levels of Brain-Derived Neurotrophic Factor and Homocysteine in peripheral blood; | — |
Countries
China
Contacts
Public ContactQiangwei Luo
Hospital of Kunming Social Welfare Institution
Outcome results
None listed